Cannabinoid analogs are novel cannabinoid compounds that are slightly modified from the naturally occurring cannabinoids in the plant. Since they have a new molecular structure that hasn’t previously existed, they are recognized as new chemical entities (NCEs). InMed’s CEO, Eric A. Adams, gives an example of a cannabinoid analog and explains how these new chemical entities are patentable. Natural cannabinoids isolated from the plant are not patentable.
Why pursue cannabinoid analogs?
Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:
- Targeting certain physiological outcomes in specific diseases;
- Improving upon the safety profile of the natural cannabinoids;
- Enhancing the ability to integrate with specific delivery technologies; and
- Protecting the long-term research investment and commercial opportunities.
InMed’s subsidiary, BayMedica, has developed a library of patentable cannabinoid analogs.